Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.


AbbVie (ABBV)

AbbVie Inc
 Apresentando as notícias mais relevantes sobre:NYSE:ABBV
20/06/202409:00PR Newswire (US)AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of DirectorsNYSE:ABBVAbbVie Inc
18/06/202419:18PR Newswire (US)U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
14/06/202417:08PR Newswire (US)AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" OfferNYSE:ABBVAbbVie Inc
13/06/202408:59PR Newswire (US)AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
11/06/202409:00PR Newswire (US)BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant RecipientsNYSE:ABBVAbbVie Inc
06/06/202409:45PR Newswire (US)AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian CancerNYSE:ABBVAbbVie Inc
06/06/202409:30PR Newswire (US)SkinMedica® Celebrates 25 Years of Empowering Radiant SkinNYSE:ABBVAbbVie Inc
06/06/202409:00PR Newswire (US)AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their CareersNYSE:ABBVAbbVie Inc
05/06/202410:00PR Newswire (US)AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383NYSE:ABBVAbbVie Inc
04/06/202409:30PR Newswire (US)RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic ArthritisNYSE:ABBVAbbVie Inc
04/06/202409:05PR Newswire (US)Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50NYSE:ABBVAbbVie Inc
03/06/202409:30PR Newswire (US)AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
31/05/202417:05Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:ABBVAbbVie Inc
31/05/202403:00PR Newswire (US)AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisNYSE:ABBVAbbVie Inc
28/05/202409:00PR Newswire (US)AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) PlatformNYSE:ABBVAbbVie Inc
23/05/202417:05PR Newswire (US)AbbVie Completes Acquisition of Landos BiopharmaNYSE:ABBVAbbVie Inc
17/05/202408:30PR Newswire (US)AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®NYSE:ABBVAbbVie Inc
13/05/202409:39PR Newswire (US)AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric DisordersNYSE:ABBVAbbVie Inc
08/05/202418:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:ABBVAbbVie Inc
08/05/202409:00PR Newswire (Canada)QULIPTA(MC) (atogépant) est maintenant approuvé par Santé Canada pour la prévention de la migraine chronique chez les adultesNYSE:ABBVAbbVie Inc
08/05/202409:00PR Newswire (Canada)QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in AdultsNYSE:ABBVAbbVie Inc
07/05/202421:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
06/05/202409:00PR Newswire (US)AbbVie to Present at the Bank of America Securities Healthcare ConferenceNYSE:ABBVAbbVie Inc
26/04/202408:47IH Market NewsU.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation DataNYSE:ABBVAbbVie Inc
26/04/202408:35PR Newswire (US)AbbVie Reports First-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
25/04/202409:00PR Newswire (US)New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyNYSE:ABBVAbbVie Inc
23/04/202409:00PR Newswire (US)Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsNYSE:ABBVAbbVie Inc
18/04/202409:31PR Newswire (US)Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisNYSE:ABBVAbbVie Inc
12/04/202408:30PR Newswire (US)AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
09/04/202409:00PR Newswire (US)SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to AcneNYSE:ABBVAbbVie Inc
 Apresentando as notícias mais relevantes sobre:NYSE:ABBV